Autologous hematopoietic transplantation for low-grade lymphomas

References

• Philip T, Guglielmi C, Hagenbeek A et al. Autologous bonemarrow transplantion as compared with salvage chemo-therapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. New Engl y Med 1995;333:1540–5.
   PubMed Web of Science ®Google Scholar
• Horning SJ. Natural history of and therapy for the indolentnon-Hodgkin's lymphomas. Semin Oncol 1993;20:75–88.
   PubMed Web of Science ®Google Scholar
• Coiffier B. Towards a cure in indolent lymphoproliferative diseases. Eur Y Cancer 1995;31:2135–7.
   Google Scholar
• Hiddeman W. Non-Hodgkin's lymphomas—current status and future perspectives. Eur y Cancer 1996;31A:2141.
   Google Scholar
• Schmitz N, Linch DC, Dreger P et al. Randomized trial offilgrastim-mobilized peripheral blood progenitor cell trans-plantation versus autologous bone-marrow transplantation in lymphoma patients. Lancet 1996;347:353–7.
   PubMed Web of Science ®Google Scholar
• Majolino I, Pearce R, Taghipour G et al. Peripheral-blood-stem-cell transplantation versus autolgous bone marrow transplantation in Hodgkin's disease and non-Hodgkin's lymphomas: a new matched-pair analysis of the European Lymphoma working party of the European Lymphoma working party of the European Group for blood and marrow transplantation. 7 Clin Oncol 1997;15: 509–17.
   Google Scholar
• Narayanasami U, Kanteti R, Morelli J et al. Randomized trialof filgrastim versus chemotherapy and filgrastim mobiliza-tion of hematopoietic progenitor cells for rescue in autologous transplantation. Blood 2001;98:2059–64.
   PubMed Web of Science ®Google Scholar
• Bakshi A, Jensen JP, Goldman P et al. Cloning the chromo-somal breakpoint of t(14;18) human lymphomas: clustering around JH on chromosome 14 and near a transcriptional unit on 18. Ce/11985;41:899–906.
   Google Scholar
• Tsujimoto Y, Cossman J, Jaffe E et al. Involvement of the bcl-2gene in human follicular lymphoma. Science1985;228:1440–3.
   PubMed Web of Science ®Google Scholar
• Cleary ML, Sklar J. Nucleotide sequence of a t(14;18) chromosomal breakpoint in follicular lymphoma and demonstration of a breakpoint cluster region near a tran-scriptionally active locus on chromosome 18. Proc Natl Acad Sci USA 1985;82:7439–43.
   PubMed Web of Science ®Google Scholar
• Ngan BY, Nourse J, Cleary ML. Detection of chromosomal translocation t(14;18) within the minor cluster region of bcl-2 by polymerase chain reaction and direct genomic sequenc-ing of the enzymatically amplified DNA in follicular lymphomas. Blood 1989;73: 1759–62.
   Google Scholar
• Limpens J, de Jong D, van Krieken JH et al. Bel-219H rearrangements in benign lymphoid tissues with follicular hyperplasia. Oncogene 1991;6:2271–6.
   Google Scholar
• Aster JC, Kobayashi Y, Shiota M et al. Detection of the 414;18) at similar frequencies in hyperplastic lymphoid tissues from American and Japanese patients. Am 7 Pathol 1992;141:291–9.
   PubMed Web of Science ®Google Scholar
• Limpens J, Stad R, Vos C et al. Lymphoma-associated translocation t(14;18) in blood B cells of normal individuals. Blood 1995;85:2528–36.
   PubMed Web of Science ®Google Scholar
• Tsujimoto Y, Yunis J, Onorato-Showe L et al. Molecular cloning of the chromosomal breakpoint of B-cell lym-phomas and leukemias with the t(11;14) chromosome translocation. Science 1984;224:1403–6.
   PubMed Web of Science ®Google Scholar
• Rimokh R, Berger F, Delsol G et al. Detection of the chromosomal translocation t(11;14) by polymerase chain reaction in mantle cell lymphomas. Blood 1994;83:1871–5.
   PubMed Web of Science ®Google Scholar
• Molot RJ, Meeker TC, Wittwer CT et al. Antigen expression and polymerase chain reaction amplification of mantle cell lymphomas. Blood 1994;83:1626–31.
   PubMed Web of Science ®Google Scholar
• Freedman AS, Neuberg D, Gribben JG et al. High-dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle-cell lymphoma: no evidence for long-term remission. 7 Clin Oncol 1998;16: 13–18.
   Google Scholar
• Andersen NS, Donovan JW, Borus JS et al. Failure of immunologic purging in mantle cell lymphoma assessed by PCR detection of minimla residual disease. Blood 1997; 90:4212–21.
   PubMed Web of Science ®Google Scholar
• Mayer R, Logtenberg T, Strauchen J et al. CD5 and immunoglobulin V gene expression in B cell lymphomas and chronic lymphocytic leukemias. Blood 1990;75:1518–24.
   PubMed Web of Science ®Google Scholar
• Bahler DW, Campbell MJ, Hart S et al. Ig VH gene expres-sion among human follicular lymphomas. Blood 1991; 78:1561–8.
   PubMed Web of Science ®Google Scholar
• Bahler DW, Levy R. Clonal evolution of follicular lym-phoma: evidence for antigen selection. Proc Natl Aca Sci USA 1992;89:6770–4.
   PubMed Web of Science ®Google Scholar
• Gribben JG, Neuberg D, Freedman AS et al. Detection by polymerase chain reaction of residual cells with the bcl-2 translocation is associated with increased risk of relapse after autologous bone marrow transplantation for B-cell lymphoma. Blood 1993;81:3449–57.
   PubMed Web of Science ®Google Scholar
• Zwicky CS, Maddocks AB, Andersen N et al. Eradication of polymerase chain reaction immunoglobulin gene rearrange-ment in non-Hodgkin's lymphoma as associated with decreased relapse after autologous bone marrow transplan-tation. Blood 1996;88:3314–22.
   PubMed Web of Science ®Google Scholar
• Corradini P, Astolfi M, Cherasco C et al. Molecular monitor-ing of minimal residual disease in follicular and mantle cell non-Hodgkin's lymphomas treated with high-dose chemo-therapy and peripheral blood progenitor cell autografting. Blood 1997;89:724–31.
   PubMed Web of Science ®Google Scholar
• Johnson PW, Price CG, Smith T et al. Detection of cells bearing the t(14;18) translocation following myeloablative treatment and autologous bone marrow transplantation for follicular lymphoma. 7 Clin Oncol 1994;12:798–805.
   PubMed Web of Science ®Google Scholar
• Apostolidis J, Gupta RK, Grenzelias D et al. High-dose therapy with autologous bone marrow support as consolida-tion of remission in follicular lymphoma: long-term clinical and molecular follow-up. 7 Clin Oncol 2000;18: 527–36.
   Google Scholar
• Ladetto M, Sametti S, Donovan JW et al. A validated real-time quantitative PCR approach shows a correlation between tumor burden and successful ex vivo purging in follicular lymphoma patients. Exp Hematol 2001;29:183–93.
   PubMed Web of Science ®Google Scholar
• Provan AB, Hodges E, Smith AG et al. Use of paraffin wax embedded bone marrow trephine biopsy specimens as a source of archival DNA. 7 Gun Pathol 1992;45:763–5.
   Web of Science ®Google Scholar
• Esteve J, Villamor N, Colomer D et al. Stem cell transplan-tation for chronic lymphocytic leukemia: different outcome after autologous and allogeneic transplantation and correla-tion with minimal residual disease status. Leukemia 2001; 15:445–51.
   PubMed Web of Science ®Google Scholar
• Freedman AS, Takvorian T, Anderson KC et al. Autologous bone marrow transplantation in B-cell non-Hodgkin's lym-phoma: very low treatment-related mortality in 100 patients in sensitive relapse. 7 Gun Oncol 1990;8:784–91.
   PubMed Web of Science ®Google Scholar
• Gribben JG, Freedman AS, Neuberg D et al. Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma. N Engl .7 Med 1991;325;1525–33.
   PubMed Web of Science ®Google Scholar
• Moos M, Schulz R, Cremer F et al. Detection of minimal residual disease by polymerase chain reaction in B cell malignancies. Stem Cells 199 5;13\(Suppl 3):42–51.
   Google Scholar
• Tarella C, Corradini P, Astolfi M et al. Negative immuno-magnetic ex vivo purging combined with high-dose chemotherapy with peripheral blood progenitor cell auto-graft in follicular lymphoma patients: evidence for long-term clinical and molecular remissions. Leukemia 1999; 13:1456–62.
   PubMed Web of Science ®Google Scholar
• Stone RM. Myelodysplastic syndrome after autologous transplantation for lymphoma: the price of progress? Blood 1994;83:3437–40.
   PubMed Web of Science ®Google Scholar
• Miller JS, Arthur DC, Litz CE et al. Myelodysplastic syn-drome after autologous bone marrow transplantation: an additional late complication of curative cancer therapy. Blood 1994;83:3780–6.
   PubMed Web of Science ®Google Scholar
• Traweek ST, Slovak ML, Nademanee AP et al. Myelodysplasia and acute myeloid leukemia occurring after autologous bone marrow transplantation for lymphoma. Leuk Lymphoma 1996;20:365–72.
   PubMed Web of Science ®Google Scholar
• Milligan DW, Ruiz De Elvira MC, Kolb HJ et al. Secondary leukaemia and myelodysplasi a after autografting for lym-phoma: results from the EBMT. EBMT Lymphoma and Late Effects Working Parties. European Group for Blood and Marrow Transplantation. Br y Haematol 1999;106:1020–6.
   Google Scholar
• Pedersen-Bjergaard J, Pedersen M, Myhre J et al. High risk of therapy-related leukemia after BEAM chemotherapy and autologous stem cell transplantation for previously treated lymphomas is mainly related to primary chemotherapy and not to the BEAM-transplantation procedure. Leukemia 1997; 11:1654–60.
   PubMed Web of Science ®Google Scholar
• Pedersen-Bjergaard J, Andersen MK. Secondary or therapy-related MDS and AML and their chromosome aberrations: important to study but difficult to establish causality. Haematologica 1998;83:481–2.
   Google Scholar
• Pedersen-Bjergaard J, Andersen MK, Christiansen DH. Therapy-related acute myeloid leukemia and myelo-dysplasia after high-dose chemotherapy and autologous stem cell transplantation. Blood 2000;95:3273–9.
   Google Scholar
• Friedberg JW, Neuberg D, Stone RM et al. Outcome in patients with myelodysplastic syndrome after autologous bone marrow transplantation for non-Hodgkin's lymphoma. 7 Gun Oncol 1999;17:3128–35.
   PubMed Web of Science ®Google Scholar
• Krishnan A, Bhatia S, Slovak ML et al. Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: an assessment of risk factors. Blood 2000;95:1588–93.
   PubMed Web of Science ®Google Scholar
• Gilliland DG, Gribben JG. Evaluation of the risk of therapy-related MDS/AML after sutologous stem cell transplanta-tion. Biol Blood Marrow Transplant 2002;8:9–16.
   PubMed Web of Science ®Google Scholar
• Cao TM, Horning S, Negrin RS et al. High-dose therapy and autologous hematopoietic-cell transplantation for follicular lymphoma beyond first remission: the Stanford University experience. Biol Blood Marrow Transplant 2001; 7:294–301.
   PubMed Web of Science ®Google Scholar
• Bastion Y, Brice P, Haioun C et al. Intensive therapy with peripheral blood progenitor cell transplantation in 60 patients with poor-prognosis follicular lymphoma. Blood 1995;86:3257–62.
   PubMed Web of Science ®Google Scholar
• Haas R, Moos M, Mohle R et al. High-dose therapy with peripheral blood progenitor cell transplantation in low-grade non-Hodgkin's lymphoma. Bone Marrow Transplant 1996; 17:149–55.
   PubMed Web of Science ®Google Scholar
• Morel P, Laporte JP, Noel MP et al. Autologous bone marrow transplantation as consolidation therapy may pro-long remission in newly diagnosed high-risk follicular lymphoma: a pilot study of 34 cases. Leukemia 1995;9: 576–82.
   PubMed Web of Science ®Google Scholar
• Freedman AS, Gribben JG, Neuberg D et al. High dose therapy and autologous bone marrow transplantation in patients with follicular lymphoma during first remission. Blood 1996;88:2780–6.
   PubMed Web of Science ®Google Scholar
• Seyfarth B, Kuse R, Sonnen R et al. Autologous stem cell transplantation for follicular lymphoma: no benefit for early transplant? Ann Hematol 2001;80:398–405.
   PubMed Web of Science ®Google Scholar
• Horning SJ, Negrin RS, Hoppe RT et al. High-dose therapy and autologous bone marrow transplantation for follicular lymphoma in first complete or partial remission: results of a phase clinical trial. Blood 2001;97:404–9.
   PubMed Web of Science ®Google Scholar
• Friedberg JW, Neuberg D, Gribben JG et al. Autologous bone marrow transplantation after histologic transformation of indolent B cell malignancies. Biol Blood Marrow Transplant 1999;5:262–8.
   PubMedGoogle Scholar
• Chen CI, Crump M, Tsang R et al. Autotransplants for histologically transformed follicular non-Hodgkin's lym-phoma. Br .7 Haematol 2001;113:202–8.
   PubMed Web of Science ®Google Scholar
• Williams CD, Harrison CN, Lister TA et al. High-dose therapy and autologous stem-cell support for chemo-sensitive transformed low-grade follicular non-Hodgkin's lymphoma: a case-matched study from the European Bone Marrow Transplant Registry. 7 Clin Oncol 2001;19: 727–35.
   Google Scholar
• Decaudin D, Brousse N, Brice P et al. Efficacy of autologous stem cell transplantation in mantle cell lymphoma: a 3-year follow-up study. Bone Marrow Transplant 2000;25:251–6.
   PubMed Web of Science ®Google Scholar
• Milpied N, Gaillard F, Moreau P et al. High-dose therapy with stem cell transplantation for mantle cell lymphoma: results and prognostic factors, a single center experience. Bone Marrow Transplant 1998;22:645–50.
   PubMed Web of Science ®Google Scholar
• Vose JM, Bierman PJ, Weisenburger DD et al. Autologous hematopoietic stem cell transplantation for mantle cell lymphoma. Biol Blood Marrow Transplant 2000;6:640–5.
   PubMed Web of Science ®Google Scholar
• Ketterer N, Salles G, Espinouse D et al. Intensive therapy with peripheral stem cell transplantation in 16 patients with mantle cell lymphoma. Ann Oncol 1997;8:701–4.
   PubMed Web of Science ®Google Scholar
• Khouri IF, Romaguera J, Kantarjian H et al. Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma. 7 Clin Oncol 1998;16: 3803–9.
   Google Scholar
• Josting A, Reiser M, Wickramanayake PD et al. Dexa-BEAM: an effective regimen for cytoreduction prior to high-dose chemotherapy with autologous stem cell support for patients with relapsed/refractory mantle-cell lymphoma. Leuk Lymphoma 2000;37:185–7.
   PubMed Web of Science ®Google Scholar
• Dreger P, von Neuhoff N, Kuse R et al. Sequential high-dose therapy and autologous stem cell transplantation for treat-ment of mantle cell lymphoma. Ann Oncol 1997;8:401–3.
   PubMed Web of Science ®Google Scholar
• Magni M, Di Nicola M, Devizzi L et al. Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion. Blood 2000; 96:869–9.
   Web of Science ®Google Scholar
• Rabinowe SN, Soiffer RJ, Gribben JG et al. Autologous and allogeneic bone marrow transplantation for poor prognosis patients with B-cell chronic lymphocytic leukemia. Blood 1993;82:1366–76.
   PubMed Web of Science ®Google Scholar
• Khouri IF, Keating MJ, Vriesendorp HM et al. Autologous and allogeneic bone marrow transplantation for chronic lymphocytic leukemia: preliminary results. 7 Clin Oncol 1994;12:748–58.
   PubMed Web of Science ®Google Scholar
• van Besien K, Keralavarma B, Devine S et al. Allogeneic and autologous transplantation for chronic lymphocytic leukemia. Leukemia 2001;15:1317–25.
   PubMed Web of Science ®Google Scholar
• Michallet M, Archimbaud E, Bandini G et al. HLA-indentical sibling bone marrow transplantation in younger patients with chronic lymphocytic leukemia. European Group for blood and marrow transplantation and the International bone marrow transplant registry. Ann Intern Med 1996; 124:311–5.
   Google Scholar
• Fefer A, Robinson N, Benyunes MC et al. Interleukin-2 therapy after bone marrow or stem cell transplantation for hematologic malignancies. Cancer 7 Sci Am 1997;3 (Suppl 1):S48–53.
   Google Scholar
• Davis TA, Hsu FJ, Caspar CB et al. Idiotype vaccination following ABMT can stimulate specific anti-idiotypeimmune responses in patients with B-cell lymphoma. Biol Blood Marrow Transplant 2001;7:517–22.
   PubMed Web of Science ®Google Scholar
• Verdonck LF, Dekker AW, Lockhorst HM et al. Allogeneic versus autologous bone marrow transplantation for refrac-tory and recurrent low-grade non-Hodgkin's lymphoma. Blood 1997;90:4201–5.
   PubMed Web of Science ®Google Scholar
• van Besien KW, Mehra RC, Giralt SA et al. Allogeneic bone marrow transplantation for poor-prognosis lymphoma: response, toxicity and survival depend on disease histology. Am .7 Med 1996;100:299–307.
   PubMed Web of Science ®Google Scholar
• van Besien KW, de Lima M, Giralt SA et al. Management of lymphoma recurrence after allogeneic transplantation: the relevance of graft versus lymphoma effect. Bone Marrow Transplant 1997;19:977–82.
   PubMed Web of Science ®Google Scholar